QTT - Chinese news app, good user growth, should have enough cash for the time being - Lock up expires March 14, 2019, 2-3 day rest pattern

 

CTK - Chinese tech company, recent IPO, should have enough cash, thin and volatile, would have to use 10.50 risk and keep position size small

 

APYX - medical device company, played this one when it was Bovie Medical (BVX), changed name as a rebranding and moved from NYSE to NASDAQ, just beat on earnings and provided good guidance, strong balance sheet according to management, CHART rules apply, currently at 52-week highs

 

VCYT - genomic diagnostic company, jumped 40% on earnings, then pulled back with the market, went slow sto 20, and now its RSI 70 and at 52-week highs, did a raise in July 2018, their burn rate for three months is $2.5million and they have $77million in cash, so I think a raise is unlikely

 

HYRE - Uber/Lyft play, this company offers vehicle owners a chance to rent their cars to the ride sharing platforms, recent IPO, should have enough cash, downtrended since IPO but could be coming back now, watch for the chart to build for now

 

INSG - 5G play, all three charts, 52-week breakout, 4.2 million warrants with exercise price of $2.52 unlock on February 6, 2019, then there's another 16 million shares that the company can use to raise cash at any time, shelf already filed, I'd rather wait for lockup to expire and short when I know selling pressure is going to come in

 

AGEN - signed collaboration agreement with $88billion giant Gilead, upfront payment of $120million, potential for $1.7billion in milestone payments, chart coming off the bottom, want to watch for now see if it can build strength UPDATE: lost chart rules, but will keep on watch for now

 

EPZM - makes cancer drug and just closed an $80million capital raise so they should have cash, coming off the bottom, watch for chart strength to hold and build

 

FUV - SWING fun utility vehicle, we know this one from last year, the CEO bought $400k worth of shares recently, and the company just announced that they secured financing and plan to deliver the first commercially available EV in Q1 this year, the capital raise was done at $3 with warrants to purchase at $3.50

AEZS - licensing deal for their growth hormone test, say they have enough cash for now, but this is a chart play, watching for now